Title:
CELL PREPARATION METHOD, AND CELL CULTURE VESSEL
Document Type and Number:
WIPO Patent Application WO/2017/200017
Kind Code:
A1
Abstract:
In order to achieve the practical use of an antigen-specific immuno-cell therapy, a cell culture vessel 1 in which multiple depressed parts 4, which serve as cell culturing sections, are provided on one surface of the walls of the vessel is used, so that cells are settled in the depressed parts 4 to prepare desired cells. In this manner, it becomes possible to appropriately prepare antigen-specific immunocytes in a large quantity, simply and safely, at low cost, and with high efficiency.
Inventors:
TANAKA SATOSHI (JP)
SUENAGA RYO (JP)
TOTANI TAKAHIKO (JP)
LI DONGLIANG (JP)
TOJI SHINGO (JP)
SUENAGA RYO (JP)
TOTANI TAKAHIKO (JP)
LI DONGLIANG (JP)
TOJI SHINGO (JP)
Application Number:
PCT/JP2017/018575
Publication Date:
November 23, 2017
Filing Date:
May 17, 2017
Export Citation:
Assignee:
TOYO SEIKAN GROUP HOLDINGS LTD (JP)
MEDICAL & BIOL LAB CO LTD (JP)
MEDICAL & BIOL LAB CO LTD (JP)
International Classes:
C12N5/078; C12M1/00; C12M3/00; A61K35/15; A61K35/17; A61P31/12; A61P35/00; C07K7/06
Domestic Patent References:
| WO2010107116A1 | 2010-09-23 | |||
| WO2011024482A1 | 2011-03-03 | |||
| WO2014112491A1 | 2014-07-24 | |||
| WO2015129790A1 | 2015-09-03 |
Foreign References:
| JP2013502235A | 2013-01-24 | |||
| JP2006055069A | 2006-03-02 | |||
| JP2005295904A | 2005-10-27 | |||
| JP2009011260A | 2009-01-22 |
Other References:
TAKAO YOSHIDA ET AL.: "Pharmacological profile and clinical efficacy of human anti-human PD-1 antibody nivolumab (OPDIVO@) as a new immune checkpoint inhibitor", FOLIA PHARMACOL. JPN., vol. 146, 2015, pages 106 - 114
Attorney, Agent or Firm:
HEIWA INTERNATIONAL PATENT OFFICE (JP)
Download PDF:
Previous Patent: THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE
Next Patent: POWER GENERATING RECHARGEABLE ELECTRIC VEHICLE
Next Patent: POWER GENERATING RECHARGEABLE ELECTRIC VEHICLE